立体定向放射治疗联合厄洛替尼治疗晚期非小细胞肺癌的疗效与安全性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (579 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the efficacy and adverse effects of γ-SBRT combinaed with targeted drug erlotinib on advanced stage non-small cell lung cancer. Methods Forty-two advanced stage non-small cell lung cancer patients were finally confirmed by pathohistological or cytological examination. All patients, after starting gamma knife radiosurgery, took orally targeted drugs erlotinib from August 2008 to August 2012,100-150 mg/d,1 hour before meal eating or 2 hours after meal, uninterrupted medication for at least 2 months. The efficacy and toxic reactions were evaluated after at least one month at the end of gamma knife radiosurgery. Results In 42 patients, the objective response rate reached 19.0%(8/42), the disease control rate reached 61.9% (26/42) , and the median time to disease progression was 5.2 months, the median survival time was 11.5 months. Major adverse effects were myelosuppression, lassitude and gastrointestinal tract reactions, most of which wereⅠ/Ⅱ degree with less being Ⅲ/Ⅳ degree. Conclusions The efficacy of γ-SBRT in combined with targeted drug erlotinib on advanced stage non-small cell lung cancer is acceptable and adverse effects are tolerable.

Key words： non-small cell lung cancer stereotactic radiation therapy targeted therapy erlotinib

Received: 09 September 2012

ZTFLH:

R730.57

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIU Shujun
	WU Junlan
	LI yong
	ZHANG Guoyu
	PAN Mianshun
	and CHEN Jian.

Cite this article:

QIU Shujun,WU Junlan,LI yong等. Efficacy of γ-SBRT combined with targeted drug erlotinib in advanced stage non-small cell lung cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2013, 24(7): 608-610.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2013/V24/I7/608

[1]	郑爱青,郑培,于金明,等. 吉西他滨单药或联合卡铂治疗老年晚期非小细胞肺癌疗效观察[J]. 武警医学,2011,22(6): 501-504.
[5]	周翔,许亚萍,马胜林,等. 吉非替尼对肺癌A549细胞系的放射增敏作用[J]. 临床肿瘤学杂志,2007,12(11):814-821.
[2]	Timmerman R D, Kavanagh B D. Stereotatic body radiation therapy[J]. Curr probl Cancer, 2005, 29(3): 120-157.
[6]	von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie[J], 2008, 31(3):123-126.
[3]	Martel M K. Advanced radiation treatment planning and delivery approaches for treatment of lung cancer[J]. Hematol Oncol Clin North Am, 2004, 18(1): 231-43.
[7]	Lind J S, Lagerwaard F J, Smit E F, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1391-1396.
[4]	卢飞,赵品婷,姚红军,等. 全身伽玛刀同步辅助化疗治疗局部晚期非小细胞肺癌的疗效观察[J]. 现代肿瘤医学,2008,16(8):1317-1318.
[8]	赵荆,付强,张莉红. 厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察[J]. 中国肺癌杂志,2009,12(12):1291-1294.
[5]	周翔,许亚萍,马胜林,等. 吉非替尼对肺癌A549细胞系的放射增敏作用[J]. 临床肿瘤学杂志,2007,12(11):814-821.
[9]	Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks[J]. Cancer Res, 2011, 71(19):6261-6269.
[6]	von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie[J], 2008, 31(3):123-126.
[10]	Perez-Soler R, Chachoua A, H ammond L A, et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2004,22(16):3238-3247.
[7]	Lind J S, Lagerwaard F J, Smit E F, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1391-1396.
[8]	赵荆,付强,张莉红. 厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察[J]. 中国肺癌杂志,2009,12(12):1291-1294.
[9]	Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks[J]. Cancer Res, 2011, 71(19):6261-6269.
[10]	Perez-Soler R, Chachoua A, H ammond L A, et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2004,22(16):3238-3247.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(7): 729-728.